THE BENEFICIAL EFFECT OF ATRIAL-NATRIURETIC-PEPTIDE ON CYCLOSPORINE NEPHROTOXICITY

被引:31
作者
CAPASSO, G
ROSATI, C
CIANI, F
GIORDANO, DR
RUSSO, F
DESANTO, NG
机构
[1] The Department of Pediatrics, School of Medicine, University of Naples, Naples
关键词
D O I
10.1093/ajh/3.3.204
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Nephrotoxicity is the most common and important side effect of cyclosporine (CyA) therapy. It is characterized by a fall in glomerular filtration rate (GFR) and by a decrease in sodium and water excretion. Since atrial natriuretic peptide (ANP) has been shown to increase GFR and to cause a potent diuretic and natriuretic effect, we have investigated the potential beneficial action of ANP on CyA induced renal injury. To this end two groups of animals were studied: 1) rats that received an intravenous infusion of CyA (20 mg/kg body weight) (acute studies) and 2) rats that have been treated with daily intraperitoneal injections of CyA (20 mg/kg body weight) for a total of seven days (chronic studies). To both groups of rats synthetic ANP was administered intravenously as a bolus (10 μg/kg) and then as a constant infusion (1 μg/kg/min). In group 1 the CyA administration resulted in a decrease in GFR, urine output, urinary sodium and potassium excretion. After ANP infusion there was a prompt restoration of GFR, with a large rise in urine, sodium and potassium excretion rates. Similar effects on renal hemody-namics and electrolyte excretion rates were detected after ANP administration in chronic CyA treatment. These data show that the administration of ANP to rats that have been exposed to acute or chronic CyA treatment is able to reverse the harmful effect of CyA on renal function. © 1990 by the American Journal of Hypertension, Ltd.
引用
收藏
页码:204 / 210
页数:7
相关论文
共 27 条
[1]  
Cyclosporine in cadaveric renal transplantation, N Engl J Med, 390, pp. 809-812, (1983)
[2]  
Capodicasa G., De Santo N.G., Nuzzi F., Giordano C., Cyclosporine A in nephrotic syndrome in childhood. 14 months experience, Int J Pediatr Nephrol, 7, pp. 69-72, (1986)
[3]  
Myers B.D., Ross J., Newton L., Et al., Cyclosporine associated chronic nephropathy, J Engl J Med, 311, pp. 699-705, (1984)
[4]  
Murray B.M., Paller M.S., Ferris T.F., Effect of cyclosporine administration on renal hemodynamics in conscious rats, Kidney Int, 28, pp. 767-774, (1985)
[5]  
Dieperink H., Leyssac P.P., Starklint H., Kemp E., Nephro toxicity of cyclosporin A. A lithium clearance and micropuncture study in rats, Eur J Clin Invest, 16, pp. 69-77, (1986)
[6]  
Ader D., Turney J., Michael J., McMaster P., Hyperkalemia in cyclosporine treated renal allograft recipients, Lancet, 2, pp. 370-372, (1983)
[7]  
Hamilton D.V., Evans D.B., Henderson R.G., Et al., Nephrotoxicity and metabolic acidosis in transplant patients on cyclosporin A, Proc Eur Dial Transplant Assoc, 18, pp. 400-409, (1981)
[8]  
Schafferhaus K., Hudbreder E., Grimm D., Heidland A., Norepinephrine-induced acute renal failure: beneficial effects of atrial natriuretic factor, Nephron, 44, pp. 240-244, (1986)
[9]  
Capasso G., Anastasio P., Giordano D., Et al., Beneficial effects of atrial natriuretic factor on cis-platin induced acute renal failure in the rat, Am J Nephrol, 7, pp. 228-234, (1987)
[10]  
Shaw S.G., Weidman P., Hodler J., Et al., Atrial natriuretic peptide protects against acute ischemic renal failure in the rat, J Clin Invest, 80, pp. 1232-1237, (1987)